Evidence map›Paper›PMID 35740139›Full record

ArticleAntibiotics (Basel, Switzerland)2022

In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against

Woraphot Tantisiriwat, Jirawat Buppanharun, Chatchai Ekpanyaskul, Kwanchai Onruang, Thitiya Yungyuen, Pattarachai Kiratisin, Somchai Santiwatanakul

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Risk Factors and Outcomes of Multidrug-resistantSaudi journal of medicine & medical sciences
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Woraphot TantisiriwatDepartment of Preventive Medicine, HRH Princess Maha Chakri Sirindhorn Medical Center, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok 26120, Thailand.
Jirawat BuppanharunDepartment of Preventive Medicine, HRH Princess Maha Chakri Sirindhorn Medical Center, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok 26120, Thailand.
Chatchai EkpanyaskulDepartment of Preventive Medicine, HRH Princess Maha Chakri Sirindhorn Medical Center, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok 26120, Thailand.
Kwanchai OnruangDepartment of Pathology, HRH Princess Maha Chakri Sirindhorn Medical Center, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok 26120, Thailand.
Thitiya YungyuenDepartment of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Pattarachai KiratisinDepartment of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Somchai SantiwatanakulDepartment of Pathology, HRH Princess Maha Chakri Sirindhorn Medical Center, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok 26120, Thailand.
Srinakharinwirot University · THMahidol University · TH

Funding

The Merck Sharp & Dohme Corp. Protocol Number 58756
6 · The paper itself

Abstract

(1) Background: Resistant

Indexed as

ceftolozane-tazobactamin vitro susceptibilityPseudomonas aeruginosa

Identifiers

PMID35740139
PMCPMC9219754
OpenAlexW4281952440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.